Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis

NCT01328379 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT01328379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01328379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
July 31, 2012
Enrollment
430 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis